JP2007505943A - 結合型エストロゲンのための組成物および関連方法 - Google Patents

結合型エストロゲンのための組成物および関連方法 Download PDF

Info

Publication number
JP2007505943A
JP2007505943A JP2006528011A JP2006528011A JP2007505943A JP 2007505943 A JP2007505943 A JP 2007505943A JP 2006528011 A JP2006528011 A JP 2006528011A JP 2006528011 A JP2006528011 A JP 2006528011A JP 2007505943 A JP2007505943 A JP 2007505943A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
component
amount
present
sugar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006528011A
Other languages
English (en)
Japanese (ja)
Inventor
トーマス ホー，
Original Assignee
ワトソン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ワトソン ファーマシューティカルズ， インコーポレイテッド filed Critical ワトソン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2007505943A publication Critical patent/JP2007505943A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006528011A 2003-09-22 2004-08-27 結合型エストロゲンのための組成物および関連方法 Withdrawn JP2007505943A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/668,104 US7303763B2 (en) 2001-02-12 2003-09-22 Compositions for conjugated estrogens and associated methods
PCT/US2004/028100 WO2005034922A1 (en) 2003-09-22 2004-08-27 Compositions for conjugated estrogens and associated methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011116320A Division JP2011157401A (ja) 2003-09-22 2011-05-24 結合型エストロゲンのための組成物および関連方法

Publications (1)

Publication Number Publication Date
JP2007505943A true JP2007505943A (ja) 2007-03-15

Family

ID=34435338

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006528011A Withdrawn JP2007505943A (ja) 2003-09-22 2004-08-27 結合型エストロゲンのための組成物および関連方法
JP2011116320A Pending JP2011157401A (ja) 2003-09-22 2011-05-24 結合型エストロゲンのための組成物および関連方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011116320A Pending JP2011157401A (ja) 2003-09-22 2011-05-24 結合型エストロゲンのための組成物および関連方法

Country Status (6)

Country Link
US (1) US7303763B2 (enExample)
EP (1) EP1689372B1 (enExample)
JP (2) JP2007505943A (enExample)
CN (2) CN1870981A (enExample)
CA (1) CA2539872C (enExample)
WO (1) WO2005034922A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US6992075B2 (en) * 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
UA95093C2 (uk) * 2005-12-07 2011-07-11 Нікомед Фарма Ас Спосіб одержання кальцієвмісної сполуки
US20090232897A1 (en) * 2008-03-14 2009-09-17 Bijayananda Sahoo Pharmaceutical compositions comprising conjugated estrogens
KR101787481B1 (ko) 2010-10-21 2017-10-18 롯데정밀화학 주식회사 장용성 경질 캡슐용 조성물 및 상기 조성물을 사용하여 제조된 장용성 경질 캡슐
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07206681A (ja) * 1993-12-23 1995-08-08 Akzo Nobel Nv １回服用量糖衣製剤
JP2001517629A (ja) * 1997-09-23 2001-10-09 アクゾ・ノベル・エヌ・ベー 被覆投与単位
WO2003051336A1 (de) * 2001-12-14 2003-06-26 Solvay Pharmaceuticals Gmbh Matrix-filmtablette mit kontrollierter freisetzung von natürlichen gemischen konjugierter oestrogene

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2565115A (en) * 1948-10-28 1951-08-21 Squibb & Sons Inc Method of obtaining a conjugated estrogen preparation
US2720483A (en) * 1951-02-21 1955-10-11 Olin Mathieson Method of obtaining a conjugatedestrogen preparation
US3487152A (en) * 1967-02-07 1969-12-30 Hoffmann La Roche Tablets containing 7 - chloro - 2 - methylamino - 5 - phenyl - 3h - 1,4 - benzodiazepine-4-oxide and conjugated estrogenic substances
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US5395627A (en) * 1992-09-04 1995-03-07 Akzo N.V. Pharmaceutical granulate
IT1270831B (it) * 1993-09-17 1997-05-13 Romano Deghenghi Composizioni farmaceutiche orali effervescenti contenenti estrone
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US6346269B1 (en) * 2000-05-08 2002-02-12 Standard Chem. & Pharm. Co., Ltd. Method for preparing an oral formulation containing acid-sensitive drugs and oral formulation made thereby
US6630166B1 (en) * 2001-02-12 2003-10-07 Watson Pharmaceuticals, Inc. Compositions for conjugated estrogens and associated methods
KR100510356B1 (ko) * 2001-02-27 2005-08-24 룀 게엠베하 운트 콤파니 카게 저장 안정성이 개선된 피복제 및 결합제를 포함하는 약제학적 제형 및 이의 제조방법
CN1165311C (zh) * 2002-04-20 2004-09-08 新疆特丰药业股份有限公司 结合雌激素药物缓释组合物及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07206681A (ja) * 1993-12-23 1995-08-08 Akzo Nobel Nv １回服用量糖衣製剤
JP2001517629A (ja) * 1997-09-23 2001-10-09 アクゾ・ノベル・エヌ・ベー 被覆投与単位
WO2003051336A1 (de) * 2001-12-14 2003-06-26 Solvay Pharmaceuticals Gmbh Matrix-filmtablette mit kontrollierter freisetzung von natürlichen gemischen konjugierter oestrogene

Also Published As

Publication number Publication date
US20040131683A1 (en) 2004-07-08
WO2005034922A1 (en) 2005-04-21
EP1689372A4 (en) 2011-08-03
CN1870981A (zh) 2006-11-29
EP1689372B1 (en) 2015-06-17
CN101637462B (zh) 2012-11-21
CA2539872C (en) 2014-05-13
JP2011157401A (ja) 2011-08-18
CA2539872A1 (en) 2005-04-21
EP1689372A1 (en) 2006-08-16
US7303763B2 (en) 2007-12-04
CN101637462A (zh) 2010-02-03

Similar Documents

Publication Publication Date Title
JP2011157401A (ja) 結合型エストロゲンのための組成物および関連方法
US9375437B2 (en) Progesterone containing oral dosage forms and kits
KR102539030B1 (ko) 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트
CZ12896A3 (en) Sugar coating agent and moulded tablet
BRPI0713565B1 (pt) processo para fabricação de uma forma de dosagem oral sólida
US20160089381A1 (en) Stability of progestogen formulations
US8022053B2 (en) Oral solid dosage forms containing a low dose of estradiol
CN107787224A (zh) 含雌四醇组分的口腔分散剂量单位
CN107750157A (zh) 含雌四醇的口腔分散片剂
JP6472063B2 (ja) 少なくとも１つの炎症性要素を呈する腸管疾患を治療するための方法
RS61812B1 (sr) Oralno-disperzibilna tableta koja sadrži estetriol
US6630166B1 (en) Compositions for conjugated estrogens and associated methods
AU2006215822B2 (en) Solid peroral contraceptive drug
CA2585095A1 (en) Oral solid dosage forms containing a low dose of estradiol
HK1140946A (en) Compositions for conjugated estrogens and associated methods
KR102210982B1 (ko) 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트
CN115804774A (zh) 一种噁拉戈利的药物组合物，包含其的药物制剂，及其应用
HK1111087A (en) Oral solid dosage forms containing a low dose of estradiol

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070720

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20070806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110325

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110325

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110401

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110426

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110524

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111227

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120425